DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: BI 456906 - Formulation A
Drug: BI 456906 - Formulation B
Drug: BI 456906 - Formulation C

First Posted Date: 2025-01-13

Last Posted Date: 2025-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06772532

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Phase 2

Recruiting

Conditions: Geographic Atrophy

Interventions: Drug: Placebo-matching BI 1584862
Drug: BI 1584862

First Posted Date: 2025-01-10

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 138

Registration Number: NCT06769048

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
East Florida Eye Institute, Stuart, Florida, United States
🇺🇸
Southeast Retina Center, PC, Augusta, Georgia, United States

and more 21 locations

A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: BI 3776528
Drug: Placebo matching BI 3776528

First Posted Date: 2024-12-20

Last Posted Date: 2025-04-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 142

Registration Number: NCT06745297

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: Survodutide
Drug: Semaglutide

First Posted Date: 2024-12-20

Last Posted Date: 2025-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06745284

Locations: 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Phase 2

Recruiting

Conditions: Macular Degeneration, Age-related
Geographic Atrophy

Interventions: Drug: BI 771716
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716

First Posted Date: 2024-12-09

Last Posted Date: 2025-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 180

Registration Number: NCT06722157

Locations: 🇺🇸
Associated Retina Consultants, Gilbert, Arizona, United States
🇺🇸
Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸
Phoenix Retina Associates, Phoenix, Arizona, United States

and more 45 locations

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: BI 3731579
Drug: Placebo matching BI 3731579
Drug: Midazolam

First Posted Date: 2024-12-04

Last Posted Date: 2025-02-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT06716190

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

Phase 1

Recruiting

Conditions: Liver Diseases
Healthy

Interventions: Drug: Zongertinib (BI 1810631)

First Posted Date: 2024-11-18

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT06692322

Locations: 🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

Phase 2

Recruiting

Conditions: Compensated Liver Cirrhosis
Metabolic Dysfunction Associated Steatohepatitis (MASH)

Interventions: Drug: BI 770371
Drug: Placebo for BI 770371

First Posted Date: 2024-11-05

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT06675929

Locations: 🇺🇸
Blessed Health Care, Miami, Florida, United States
🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Catalina Research Institute, LLC-Montclair-49051, Montclair, California, United States

and more 9 locations

A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin hydrochloride
Drug: BI 1815368

First Posted Date: 2024-10-23

Last Posted Date: 2025-03-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06655220

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517 formulation 1
Drug: BI 690517 formulation 2
Drug: Probenecid

First Posted Date: 2024-10-18

Last Posted Date: 2025-01-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT06647810

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy